Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme (GBM), breast cancer (BC) that has metastasized to the brain, gastroesophageal adenocarcinoma (GEA) or pancreatic ductal adenocarcinoma (PDAC) expected to overexpress alpha-v beta 3 (αvβ3) and alpha-v beta 5 (αvβ5) integrins.

Study Overview

• Status: Recruiting
• Conditions: Brain Neoplasms; Glioblastoma Multiforme; Gastroesophageal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma
• Intervention / Treatment: Drug: 68Ga-FF58

Detailed Description

Approximately 80 patients will be enrolled into the study, 20 patients with GBM, 20 patients with BC that has metastasized to the brain, 20 with GEA and 20 with PDAC.

The study will have an imaging characterization part and an expansion part. In the imaging characterization part, approximately 24 patients will be enrolled, 6 with r/r GBM, 6 with BC that has metastasized to the brain, 6 with GEA and 6 with PDAC.

Both parts of the study (imaging characterization and expansion) will include a dosimetry sub-group in which the distribution, pharmacokinetics (PK), radiation dosimetry and absorbed doses in tissue and tumor will be assessed.

All patients enrolled in the study will receive a single dose of [68Ga]-FF58 and undergo [68Ga]-FF58 PET imaging at different timepoints on Day 1 as well as conventional imaging (high resolution CT or MRI).

The estimated study duration for each individual patient is approximately 44 days (including screening period of 28 days and 14 days of follow-up (FU)).

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Novartis Pharmaceuticals; Phone Number: 1-888-669-6682; Email: novartis.email@novartis.com
• Study Contact Backup: Name: Novartis Pharmaceuticals; Phone Number: +41613241111; Email: novartis.email@novartis.com

Study Locations

• France
  • Lyon, France, 69373
    • Completed
    • Novartis Investigative Site
• Germany
  • Essen, Germany, 45147
    • Recruiting
    • Novartis Investigative Site
• United States
  • California
    • Duarte, California, United States, 91010 3000
      • Withdrawn
      • City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1)
  • Texas
    • Houston, Texas, United States, 77030
      • Withdrawn
      • Uni of TX MD Anderson Cancer Cntr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study
• Patients with histologically or cytologically confirmed and documented r/r GBM that has progressed after prior radiation therapy and have not received prior bevacizumab OR patients with BC that has metastasized to the brain and who should have at least one newly diagnosed brain metastasis that has not been resected or irradiated, or has been irradiated and progressed OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic GEA (i.e., adenocarcinoma of the stomach (intestinal subtype), esophagus, or gastroesophageal junction), either untreated or r/r after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic PDAC, either untreated or r/r after one or more lines of treatment.

Exclusion Criteria:

• Creatinine clearance (calculated using Cockcroft-Gault formula) <40 mL/min.
• Unmanageable bladder outflow obstruction or urinary incontinence.
• QTcF > 480 msec on screening ECG or congenital long QT syndrome.
• Any condition that requires chronic treatment with anticoagulants or antiplatelet agents
• Patients with a known bleeding disorder
• Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]-FF58.
• Pregnant women. Women who are breastfeeding must express and discard breast milk for 12 hours after [68Ga]-FF58 administration and must also stop breast feeding during this same period. Males and females must abstain from sexual intercourse for 12 hours after [68Ga]-FF58 administration.
• Total bilirubin > 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN) or direct bilirubin > 1.5 x ULN
• Alanine aminotransferase (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN
• Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Glioblastoma Multiforme; All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].	Drug: 68Ga-FF58; Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
Experimental: Brain Metastasis from Breast Cancer; All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].	Drug: 68Ga-FF58; Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
Experimental: Gastroesophageal adenocarcinoma; All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]	Drug: 68Ga-FF58; Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
Experimental: Pancreatic ductal adenocarcinoma; All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]	Drug: 68Ga-FF58; Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non-decay corrected tissue time-activity curves (TACs) from 68Ga-FF58 PET/CT images	Time activity curves (TACs) for the various organs will be produced as non decay-corrected fraction of injected activity (%IA) per organ.	[68Ga]-FF58 PET imaging acquired at Day 1
Number of lesions detected by [68Ga]-FF58	The preliminary targeting properties of [68Ga]-FF58 will be assessed by summarizing the number of lesions identified by Positron Emission Tomography (PET), as well as by tumor type.	[68Ga]-FF58 PET imaging acquired at Day 1
Number of Participants with Lesions detected by [68Ga]-FF58 per Location	The preliminary targeting properties of [68Ga]-FF58 will be assessed by summarizing the location of lesions identified by PET, as well as by tumor type.	[68Ga]-FF58 PET imaging acquired at Day 1
Standard Uptake Value (SUV) mean and max in lesions detected by PET scans	Targeting properties of 68GaFF58 will be evaluated by semi quantitatively assessing radiotracer uptake at lesion level, identified via PET/CT imaging (4 scans). The SUVmean and SUVmax of each lesion will be calculated and reported by lesion location with summary statistics.	[68Ga]-FF58 PET imaging acquired at Day 1
Tumor to Background Ratio (TBR) of lesions detected by PET scans	Targeting properties of 68Ga-FF58 will be evaluated by semi quantitatively assessing radiotracer uptake at lesion level, identified via PET/CT imaging (4 scans). The lesion Tumor to Background Ratio (TBR) will be defined as the ratio of the lesion SUV over the reference region SUV. TBRs will be calculated for both SUVmax(lesion) / SUVmean and reported by lesion location with summary statistics. Different regions will be used as reference, in order to satisfy the most appropriate one for each type of lesion.	[68Ga]-FF58 PET imaging acquired at Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Treatment Emergent Adverse Events	Treatment-emergent adverse events (TEAEs) will be collected from first dosing (single administration, Day 1) up to last follow-up visit or the patient withdrew consent. The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.	From first dosing (single administration, Day 1) up to 14 days post infusion
Percentage of lesions detected by conventional scans, PET scans, or both modalities	The percentage of lesions detected by conventional imaging (high resolution CT or MRI acquired jointly or within 24 hours before or after the [68Ga]-FF58 PET scan), [68Ga]-FF58 PET scans , or both modalities will be summarized descriptively for all patients and split by indication.	[68Ga]-FF58 PET imaging acquired at Day 1
Lesion-level analyses of diagnostics by [68Ga]-FF58 compared with conventional imaging	At lesion level, overall, positive, and negative agreement of [68Ga]-FF58 will be calculated based on the aforementioned tabulations as follows: • Overall agreement = 100% x (Double positive + Double negative) / total number of lesions identified by either imaging procedures; Positive agreement = 100% x Double positive / (Double positive + Comparator single positive); Negative agreement = 100% x Double negative / (Double negative + Comparator single negative).	[68Ga]-FF58 PET imaging acquired at Day 1
Dosimetry Group: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity-based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. AUClast will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Tmax will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Observed maximum plasma concentration (Cmax) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Cmax will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Terminal elimination half-life (T^1/2) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. The half-life will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. AUCinf will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Total systemic clearance for intravenous administration (CL) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. CL will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Volume of distribution during the terminal phase following intravenous elimination (Vz) of 68Ga-FF58	Venous whole blood samples will be collected and analysed for radioactivity. Radioactivity based concentration units will be converted to mass-based concentration units using the specific activity of the dose at the time of manufacture (MBq/µg). Pharmacokinetics characterization will be performed on mass-based concentrations. Vz will be listed and summarized using descriptive statistics.	Day 1 (0, 0-5, 10, 30, 60, 120, 180-240, 300 minutes post infusion)
Dosimetry Group: Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA)	Urine samples will be collected over specified time intervals and analysed for radioactivity. The radioactivity excreted in each interval as a percentage of injected activity (%IA) will be listed and summarized using descriptive statistics.	Day 1 (0-30, 30-120, 120-180, 180-300 minutes post infusion)
Dosimetry Group: Absorbed dose of 68Ga- FF58	The absorbed dose in target organs will be summarized with descriptive statistics. Lesion number will be assigned by dosimetry expert.	[68Ga]-FF58 PET imaging acquired at Day 1
Dosimetry Group: Effective whole-body dose of 68Ga- FF58	The effective radiation dose will be summarized with descriptive statistics. Lesion number will be assigned by dosimetry expert.	[68Ga]-FF58 PET imaging acquired at Day 1

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals
• Investigators: Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): October 14, 2021
• Primary Completion (Estimated): July 23, 2024
• Study Completion (Estimated): July 23, 2024

Study Registration Dates

• First Submitted: December 11, 2020
• First Submitted That Met QC Criteria: January 14, 2021
• First Posted (Actual): January 15, 2021

Study Record Updates

• Last Update Posted (Actual): February 2, 2024
• Last Update Submitted That Met QC Criteria: February 1, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Breast Cancer; Glioblastoma Multiforme; GBM; Dosimetry; Pancreatic ductal adenocarcinoma; PDAC; 68Gallium; 68Ga; αvβ3; BC; Brain Metastasis from BC; Gastroesophageal adenocarcinoma; GEA; alpha-v beta 3 integrin; alpha-v beta 5 integrin; αvβ5; FF58; [68Ga]-FF58
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Central Nervous System Neoplasms; Nervous System Neoplasms; Glioblastoma; Adenocarcinoma; Brain Neoplasms
• Other Study ID Numbers: CAAA504A12101; 2020-004038-39 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No